MetLife Investment Management LLC Grows Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

MetLife Investment Management LLC raised its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 4.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,360 shares of the biopharmaceutical company’s stock after acquiring an additional 3,752 shares during the period. MetLife Investment Management LLC owned approximately 0.05% of TG Therapeutics worth $2,539,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of TGTX. Quadrant Capital Group LLC lifted its position in TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 975 shares during the last quarter. Blue Trust Inc. raised its position in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 371 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp grew its position in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 1,737 shares in the last quarter. Finally, Synergy Asset Management LLC purchased a new stake in TG Therapeutics during the fourth quarter valued at approximately $75,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Up 2.6 %

Shares of NASDAQ:TGTX opened at $41.33 on Monday. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The business’s 50 day moving average is $37.18 and its 200 day moving average is $32.59. The stock has a market cap of $6.56 billion, a P/E ratio of -413.26 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. Sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.